So, the genes of PPDT-Module 2 enriched significantly in these functions, may act as PCOS and T2D disease genes and drug targets (Figure (Figure2B), 2B), such as PPARG. Known T2D drug targets NCOA1 and PPARA, T2D disease genes HNF4A, and the PCOS disease genes AR, CYP11A1 were also enriched in same functional categories and pathways of PPARG.
The increased patient cost burden at age 65 years and a modest reduction in overall T2D drug utilization suggest that as people with T2D age into Medicare, there is potentially an increase in nonadherence and diabetes complications, the authors write. Abstract/Full Text
The risk of T2D was somewhat greater for high-intensity statins (rosuvastatin, atorvastatin, simvastatin) compared to low- and medium-intensity statins. Importantly, an increased risk of incident T2D by statins was comparable with the risk of T2D of other drugs (beta-blockers and thiazide diuretics) used for the prevention of CVD.
It is estimated that CKD affects more than 190 million people with T2D worldwide. CKD in T2D is the main cause of end stage kidney disease, which requires dialysis or a kidney transplant to stay alive. Patients with CKD and T2D are three times more likely to die from a cardiovascular-related cause than those with T2D alone.
Table 1. Examples of Drug Repurposing for the Treatment of T2D - Repurposing Drugs to Target the Diabetes Epidemic.
In T2D patients, treatment with metformin is associated with reduced blood Mg2 levels. To investigate how T2D and metformin affect Mg2 homeostasis db/m and db
The risk of T2D was somewhat greater for high-intensity statins (rosuvastatin, atorvastatin, simvastatin) compared to low- and medium-intensity statins. Importantly, an increased risk of incident T2D by statins was comparable with the risk of T2D of other drugs (beta-blockers and thiazide diuretics) used for the prevention of CVD.
Dipeptidyl peptidase 4 (DPP-4) inhibitors are drugs used to treat type 2 diabetes (T2D). They help lower blood sugar (glucose) by increasing the levels of certain hormones. Four DPP-4 inhibitors are currently approved to treat people with T2D. DPP-4 inhibitors are not the first treatment option for T2D.
T2D is a chronic disease affecting people of all ages. The incidence and prevalence of T2D in children and adolescents are increasing globally.5 In the US, there are
Comments